Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in Close of $3.4 Million Underwritten Public Offering of Common Stock - August 1, 2020
- Relief for Retirement Account Owners During COVID-19 - July 30, 2020
- Sichenzia Ross Ference LLP Represents Immuron Limited in $20 Million Registered Direct Offering - July 24, 2020